Novartis Ag

Novatis Ag

Wolfgang Jahnke

Pascal Furet

Paul William Manley

Jean-Michel Rene Rondeau

Joseph Schoepfer

Andreas Marzinzik

Robert Martin Grotzfeld

Bahaa Salem

Xavier Francois Andre Pelle

Darryl Jones

Saliha Moussaoui

Sven Weiler

Stephanie Kay Dodd

Simona Cotesta

Leo Widler

Jean Michel Rondeau

Erich Alois Spieser

The present invention relates to compounds of formula (I): 

Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

The present invention relates to compounds of formula I: 

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

The present invention relates to compounds of formula I: in which Y, Y, Y, Y, Y, R, R, Rand Rare defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers. 

C-C-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of Rand Ris hydrogen and the other is C-C-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.

Growing community of inventors

Lorrach, Germany

Wolfgang Jahnke